Professor Junfang Yang: Clinical Research and Practice of CD7 CAR-T Therapy in Relapsed/Refractory Hematologic Malignancies
On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, co-hosted by the Beijing Health Promotion Association and the Guangzhou Hongmian Oncology & Rare Disease Public…
2025 COMB丨Professor Peng Yuan: Multi-Gene Testing Drives Personalized Treatment and Illuminates a New Era in Precision Breast Cancer Care
Editor’s Note: The 8th Conference on Oncology Precision Medicine and the 11th Conference on Individualized Therapy for Breast Cancer were recently held in Beijing, jointly organized by the Beijing Breast…
Professor Ping Zhang at COMB 2025: Breaking Through Endocrine Resistance—New Precision Pathways for HR+/HER2- Breast Cancer
Editor’s Note: Endocrine resistance is one of the major challenges in the treatment of HR+/HER2- breast cancer. At the 8th Conference on Oncology Precision Medicine and the 11th Conference on…
Academician Xishan Hao: The Mission of Advancing Chinese Oncology and Building Academic Journal
Editor’s Note: With China’s rapidly aging population, cancer prevention and treatment face new challenges and opportunities. As the birthplace of modern oncology in China, Tianjin Medical University Cancer Institute and…
Professor Xiaowei Qi: Preferred Neoadjuvant Strategies in HER2-Positive Breast Cancer and Breakthrough Directions in TNBC Immunotherapy
Editor’s Note: The 2025 Summer Breast Cancer Forum · Northern Salon was held in Qingdao, Shandong, from August 8–10. Upholding the spirit of “learning and innovation” and the tradition of…
Professors Xuening Ji & Yuhua Song: Rescue Therapy in TNBC—Which Immunotherapy Combination Should Be Preferred?
Editor’s Note: In the rescue treatment of advanced triple-negative breast cancer (TNBC), should immunotherapy be combined with chemotherapy or with antibody–drug conjugates (ADCs)? At the 2025 Summer Breast Cancer Forum…